These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 11442641)

  • 1. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.
    Gensana M; Altisent C; Aznar JA; Casaña P; Hernández F; Jorquera JI; Magallón M; Massot M; Puig L
    Haemophilia; 2001 Jul; 7(4):369-74. PubMed ID: 11442641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients.
    Kallas A; Talpsep T
    Haemophilia; 2001 Jul; 7(4):375-80. PubMed ID: 11442642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
    Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K
    Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
    Berntorp E
    Haemophilia; 2007 Dec; 13 Suppl 5():69-72. PubMed ID: 18078401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes.
    Gilles JG; Lavend'homme R; Peerlinck K; Jacquemin MG; Hoylaerts M; Jorieux S; Mazurier C; Vermylen J; Saint-Remy JM
    Thromb Haemost; 1999 Jul; 82(1):40-5. PubMed ID: 10456452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitope specificity of anti-FVIII antibodies during immune tolerance therapy with factor VIII preparation containing von Willebrand factor.
    Kallas A; Pooga M; Benhida A; Jacquemin M; Saint-Remy JM
    Thromb Res; 2002 Sep; 107(6):291-302. PubMed ID: 12565716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibody to factor VIII that has less reactivity to factor VIII/von Willebrand factor complex.
    Amano K; Arai M; Koshihara K; Suzuki T; Kagawa K; Nishida Y; Fukutake K
    Am J Hematol; 1995 Aug; 49(4):310-7. PubMed ID: 7639276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of VWF in the immunogenicity of FVIII.
    Lacroix-Desmazes S; Repessé Y; Kaveri SV; Dasgupta S
    Thromb Res; 2008; 122 Suppl 2():S3-6. PubMed ID: 18549909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
    Yada K; Nogami K; Shima M
    Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
    Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
    J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors.
    Bravo MI; Da Rocha-Souto B; Grancha S; Jorquera JI
    Haemophilia; 2014 Nov; 20(6):905-11. PubMed ID: 25156825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice.
    Kallas A; Kuuse S; Maimets T; Pooga M
    Thromb Res; 2007; 120(6):911-9. PubMed ID: 17376515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM; Shi Q; Bonanad S; Klamroth R
    Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of bleeding disorders: basic science.
    Ofosu FA; Santagostino E; Grancha S; Marco P
    Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
    Saenko EL; Shima M; Gilbert GE; Scandella D
    J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.
    Delignat S; Repessé Y; Navarrete AM; Meslier Y; Gupta N; Christophe OD; Kaveri SV; Lacroix-Desmazes S
    Haemophilia; 2012 Mar; 18(2):248-54. PubMed ID: 22044692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation.
    Salvagno GL; Astermark J; Ekman M; Franchini M; Guidi GC; Lippi G; Poli G; Berntorp E
    Haemophilia; 2007 Jan; 13(1):51-6. PubMed ID: 17212725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.